Background: Colorectal cancer is one of the primary causes of cancer-related deaths and 5-fluorouracil (5-FU) therapy remains the cornerstone of treatment in these patients. Resistance to 5-FU represents a major obstacle; therefore, finding new predictive and prognostic markers is crucial for improvement of patient outcomes. Recently a new type of programmed cell death was discovered-necroptosis, which depends on receptor interacting protein 3 (RIPK3). Preclinical data showed that necroptotic cell death is an important effector mechanism of 5-FU-mediated anticancer activity.
Colorectal cancer (CRC) is one of the leading causes of morbidity and cancer-related death worldwide [1] . The 5-year survival rate for patients with CRC has risen over the past several decades and now approaches 60%. Despite the fact that CRC can be prevented or cured if diagnosed early, approximately 25% of patients present with synchronous metastases at the time of diagnosis and almost 50% of patients are expected to develop metastases, resulting in high mortality rates [2] . Most of the chemotherapy regimens are 5-fluorouracil (5-FU) -based. Resistance towards 5-FU is a key challenge in the treatment of these patients; therefore, finding reliable, predictive and prognostic markers is crucial for the improvement of patient outcomes.
Recently, a new type of programmed cell death called "necroptosis" has been discovered [3, 4] . Similar to apoptosis, this process is tightly regulated by distinct molecules and has morphological features of both necrosis and inflammation. Nevertheless, the exact pathways activating this programmed necrosis are not yet fully understood. It has been shown that tumor necrosis factor alpha (TNF-α) is the trigger factor for the formation of a complex (necrosome) in the cytoplasm between receptor-interacting protein kinase 1 (RIPK1) and receptor-interacting protein kinase 3 (RIPK3) [5, 6] . In the formation process of this complex, RIPK3 phosphorylates RIPK1, which is an essential step for inducing necroptosis [7] . In vitro and in vivo data have shown that necroptotic cell death is an important effector mechanism of 5-FU-mediated anti-tumoral activity [8, 9] .
The aim of our retrospective study was to evaluate the predictive and prognostic performance of RIPK3 expression in primary tumors in 74 patients with metastatic colon cancer.
Methods

Patient selection
In this retrospective study we reviewed the cases of 74 patients with metastatic colon cancer who were treated with first line 5-FU based regimen between January 1, 2012 and December 31, 2015 at UMHAT St. Marina, Varna, Bulgaria. Available archival tissue samples from the 74 patients were collected. The procedure was approved by the Scientific Research Ethics Committee at the Prof. Dr. Paraskev Stoyanov Medical University in Varna. The tumor response was assessed according to the Response Evaluation Criteria in Solid Tumors (ver.1.1) (RECIST 1.1). Patients were staged before treatment by performing computed tomography (CT) or positron emission tomography. The patient data, which included demographic information, radiological test results, disease characteristics and therapy regimens were retrospectively obtained from the department's archive of patients' files.
Immunohistochemical staining
Specimens of primary colon adenocarcinoma were obtained from 74 patients at the Clinical Pathology Department at St.Marina University Hospital. The diagnosis was microscopically confirmed by a pathologist. All hematoxylineosin-stained specimens contained cancerous tissues. Fivemicrometer sections were cut from the paraffin blocks and placed on glass slides. Sections were deparaffinized with xylene and dehydrated in a graded series of ethanol to DI water. Antigen retrieval was performed in the pre-heated EnVision FLEX Target Retrieval Solution (working solution) in PT Link tanks and incubated for 30 minutes at 97°C at pH=9. After cooling, the slides were placed in a diluted, at room temperature FLEX Wash Buffer (20x) for 1-5 minutes. Sections were stained by using FLEX protocol in Dako Autostainer/Autostainer Plus. Samples were tested with recombinant rabbit polyclonal antibody to RIPK3 (ABCAM's RabMab technology ab56164). The antibody (Anti-RIPK3, diluted 1:100) was incubated for 20 minutes. Detection of expression levels of RIPK3 was achieved by using the UltraVision detection system Anti-polyvalent, HRP/DAB. Finally, the reaction was visualized by the appropriate substrate-chromogen (DAB, Diaminobenzidine) reagent. Counterstaining was done using Mayer's haematoxylin for the evaluation of immunostaining. Digital images were obtained using the Leica Aperio ScanScope AT2 device (Aperio Technologies, Vista, CA) and further analyses of the scanned images were performed with the V12.1.0.5029 (Aperio) ImageScope.
H-score assessment
Two independent pathologists, with no prior knowledge of the clinical data, scored all immunohistochemically-stained specimens of RIPK3, based on the staining intensity and the percentage of positively stained tumor cells. The H-score was defined as the percentage of cells with weak stain intensity, plus two times the percentage of cells with moderate stain intensity, plus three times the percentage of cells with strong stain intensity [10] . The median value of these was used to group cases into two categories of low (≤median; 62.5 ± 35. 
KRAS Mutational Analysis
Tissue sections were examined under microscope using hematoxylin and eosin staining. The samples were then manually macrodissected and DNA was extracted from paraffin-embedded formalin-fixed tumor tissue and Kirsten rat sarcoma viral oncogene homolog (KRAS) mutational status was determined by allele-specific real-time PCR-based assay (AMOY Dx KRAS Seven Mutations Detection Kit, Amoy Diagnostics Co., Ltd., China) in the National Genetic laboratory in Sofia, Bulgaria.
Endpoints
Clinical benefit rate (CBR) was defined as the proportion of patients with a partial response or stable disease for at least six months. No patients with complete response were recorded. The clinical tumor response was assessed by CT or positron emission tomography every three months, according to the Response Evaluation Criteria in Solid Tumors (ver.1.1) [11] . Progression free survival (PFS) was defined as the time elapsed between treatment initiation and tumor progression or death from any cause. Overall survival (OS) was defined as the interval between diagnosis of the disease and death or date of last follow-up evaluation.
Statistical design and analysis
Data were managed and analyzed using SPSS software ver. 23. The Mann-Whitney U test, χ2 test and Spearman correlation were used to compare and evaluate the correlations between the expression of RIPK3 in primary tumors and the clinicopathological characteristics of the patients such as age, gender, KRAS status, histopathological grading, PS (ECOG)-performance status (Eastern Cooperative Oncology Group), CEA (carcinoembrynoic antigen), number of metastatic sites and primary tumor location (left or right). Odds ratios (ORs) with confidence intervals (CIs) for categorical outcomes were calculated using a binary logistic regression model. Survival curves according to the RIPK3 expression in primary tumors were estimated using the Kaplan-Meier method, and differences were assessed using the log-rank test. Hazard ratios (HRs) and 95 percent confidence intervals for univariate and multivariate models were computed with the use of Cox proportional-hazards regression models. Two-tailed p-values (<0.05) were considered significant.
Results
Patient characteristics
In this retrospective study, we included 74 colon cancer patients with unresectable metastatic disease who received first line 5-FU-based chemotherapy. Each of the patients' performance status was assessed to be < 2. The correlation between RIPK3 expression and clinicopathological characteristics is shown in 
Correlation between RIPK3 expression and clinicopathological parameters
All (Table 1) .
Effects of RIPK3 expression on CBR, PFS and OS
The CBR (PR+SD for at least six months) was 35.1%. Patients with low level of RIPK3 expression showed significantly lower response rates than patients with highlevel RIPK3 expression (n=6, 16.2% vs n=20, 54.1%). Moreover, considering chemotherapy response in terms of CBR, high expression of RIPK3 might be a positive predictive marker for response rate (OR 0.165, 95% CI 0.05-0.49, P = 0.01). No patients with complete response were recorded. Patients with high expression levels of RIPK3 in the primary tumor showed significantly longer mean PFS of 8.4 months (95% CI, 6.4-10.3) as compared with those with low expression levels of 5.6 months (95% CI, 4.4-6.8) (log rank test p= 0.02) (Figure 2 ). Furthermore, in univariate analysis, high expression levels of RIPK3 in patients were associated with lower risk of disease progression HR 0.61 (95% CI, 0.38-0.97; p=0.044). In the multivariate analysis, high-level RIPK3 expression was an independent predictive factor for longer PFS (HR 0.60, 95% CI 0.37-0.98, P = 0.045) ( Table  2) .
Patients with high expression levels of RIPK3 also had significantly longer mean OS (29.3 months; 95% CI, 20.8-37.8) compared with those with low expression levels (18.5 months; 95% CI, 15.06-21.9) (log rank test p= 0.036) (Figure 3) . Also, in the univariate analysis, high level of RIPK3 expression and good performance status were associated with a longer OS HR (0.59; 95% CI, 0.35-0.98; p=0.044) and HR (0.55; 95% CI, 0.32-0.92; p=0.02), respectively. These associations were not apparent in the multivariate analysis ( Table 3) . As expected, differentiation of the tumor was an independent prognostic marker for survival.
FIGURE 2. Comparison of progression free survival based on RIPK3 expression levels
Kaplan-Meier estimates of progression free survival (PFS) according to RIPK3 expression in primary tumors of metastatic colon cancer patients (categorized as high and low compared with the median). There was a significant difference in the mean PFS between groups with high and low RIPK3 expression (low RIPK3 expression mean 5.6 months; 95% CI, 4.4 -6.8 vs high RIPK3 expression mean 8.4 months; 95% CI, 6.4 -10.3, log rank test p=0.02). 
Discussion
The introduction of targeted agents has been shown to lead to a significant improvement in the progression-free and overall survival of patients with metastatic colon cancer [12] . Despite the advances in colorectal treatment and the increased knowledge of the relevant molecular pathways, our understanding of why some people benefit from treatment whereas others do not remains poor. Necroptosis is a caspase-independent type of cell death, which exhibits morphological characteristics, such as swelling of organelles and plasma membrane rupture, and is involved in the pathogenesis of many human diseases including cancer [4, 13] . Fluorouracil, an analog of uracil, is an anticancer prodrug that is converted intracellularly into three main, active metabolites. The beneficial effect of 5-FU-based chemotherapy has been linked to expression levels of several g enes including thymidylate synthase (TS) and dihydropyrimidine dehydrogenase [14] . High levels of intratumoral expression of TS are a strong predictive marker for poor response to 5-FU based chemotherapy regimens in CRC [15] . Fluorouracil resistance is a major clinical problem in the treatment of CRC [16] . Although 5-FU has been traditionally investigated for its potential to induce apoptosis, alternative forms of programmed cell death have been identified recently [17, 18] . Similarly to apoptosis, necroptosis is mediated by cascade-like signalling pathways, but does not require the activation of caspases. Programmed necrosis mediated by RIPK3 has recently been characterized as a novel mechanism to induce cell death, with major functional importance in several organs, including the colon [4] .
Cell culture experiments in human cell lines have demonstrated that the association of RIPK1 and RIPK3, as induced by TNF-α stimulation, serves as a key initial step in programmed necrosis [3] . Although the precise molecular mechanism of necroptosis remains unknown, it is believed that necroptosis is triggered when apoptosis is inactive and leads to rapid plasma membrane permeabilization, release of intracellular contents and exposure of damage-associated molecular patterns [19] . Results from several studies support the idea that RIPK1-RIPK3-dependent necroptosis machinery may be a possible mechanism to limit tumor formation and progression [20] .
Preclinical data with colon cancer cell lines have shown that administration of pan-caspase inhibitors blocks cleavage of RIPK3 and triggers necroptosis [20] . Treatment with 5-FU induces autocrine production of TNF-α, which shows that induction of necroptosis is an important effector mechanism of 5-FU-mediated anticancer activity [8] . In addition, in vivo xenograft experiments have demonstrated that a pan-caspase inhibitor, in combination with 5-FU, act synergistically to block tumor growth as compared with 5-FU alone. Notably, ex vivo experiments from this study showed that, when pretreated with pan-caspase inhibitor, more than 50% of fresh sliced tumor specimens from colorectal cancer patients produce more cell death by necroptosis in response to 5-FU. The RIPK3 expression prior to treatment was found to be crucial for the effect of conventional chemotherapeutics [21] .
Others found that the expression levels of RIPK1 and RIPK3 were reduced in primary colon cancer tissues in comparison with normal adjacent tissues; this study, however, could not prove that these proteins play a major role in the chemotherapeutic agent-induced cell death of colon cancer cells [22] .
Our results suggest that the expression level of RIPK3 in primary tumors might be a novel independent potential predictive biomarker of progression-free survival in patients with metastatic colon cancer. Furthermore, we found an association between expression of RIPK3, an essential marker of necroptosis, and CBR. High expression of RIPK3 was associated with a better OS, which makes RIPK3 a potential prognostic marker in patients with metastatic colon cancer disease.
Our study also indicated that high expression of RIPK3 in the primary tumor of patients was associated with a better survival prognosis in the univariate analysis, which suggests that necroptosis is an important determining factor of cancer cell death and outcome in patients with metastatic colon cancer. Several other studies reported the prognostic significance of markers of necroptosis in pancreatic and cervical cancer [23, 24] .
Although the statistical power of our investigation is limited by the small cohort size, the current retrospective study suggests that patients with high expression of RIPK3
FIGURE 3. Comparison of overall survival based on RIPK3 expression levels
Kaplan-Meier estimates of overall survival (OS) according to RIPK3 expression in patients with metastatic colon cancer (categorized as high and low compared with the median). There was a significant difference in the mean OS between groups with high and low RIPK3 expression (low RIPK3 expression; mean 18.5 months; 95% CI, 15 -21.9 vs high RIPK3 expression; mean 29.3 months; 95% CI, 20.8 -37.9, log rank test p=0.036) in the primary tumor could benefit mostly from treatment with 5-FU based first-line chemotherapy. A significant limitation of our study is the absence of information on whether the expression level of RIPK3 in pretreatment biopsy samples correlates with the expression of all metastatic sites.
Despite these limitations, this study opens a gateway for the investigation of RIPK3 as potential marker to identify appropriate patients for a new pro-necroptotic therapy in clinical trials to improve patient outcomes.
